1.	Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000675520, NCCTG-N09C6, N09C6, NCT01156142
2.	Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 603EUSA03, NCT00901732
3.	Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 06-121, 1R21CA130241-01A1, NCT00903461
4.	Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO # 06-0509, NCT00970502
5.	A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WCI1761-09, NCT01283334
6.	E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7050-702, 2011-000773-31, NCT01332266
7.	Induction Therapy-Docetaxel, Cisplatin and Fluorouracil in Untreated Advanced Squamous Cell or Undifferentiated Carcinoma of the Paranasal Sinuses Phase: Phase II Type: Treatment Status: Active Age: Over 16 Sponsor: Other Protocol IDs: 2007-0433, NCT00707473
8.	Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: GRID, NCT00765570
9.	Preoperative Treatment With Cetuximab and/or IMC-A12 Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0342, NCT00957853
10.	Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 09-083, NCT00968435
11.	A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 090214, 09-C-0214, NCT00978250
12.	A Study in Head and Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13420, I4E-MC-JXBB, NCT01063075
13.	Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: ENT0033, SU-08222011-8290, 22329, NCI-2011-03271, NCT01437449
14.	Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 10-308, 2P01CA021239-29, NCT01586767
15.	Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01640, 12-1359, N01CM00071, NCT01696955
16.	Vaccine Therapy in Treating Patients With Head and Neck Cancer Phase: Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: NCI, Other Protocol IDs: CDR0000515081, PCI-03-156, PCI-0507062, NCT00404339
17.	Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 05-0108-04, P30CA023074, UARIZ-05-0108-01, UARIZ-HSC0529, UARIZ-SRC17855, LILLY-UARIZ-05-0108-01, 05-0108-01, NCT01172028
18.	Four Doses of MAGE Vaccine for Patients With Squamous Cell Carcinoma of the Head and Neck Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: HP-41372, UMGCC 0804, NCT00704041
19.	Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000635094, BUMC-H-26649, H-26649, NCT00851253
20.	Phase I Study of Blood Oxygen Level Dependant Functional MRI for the Detection of Hypoxia in Patients Undergoing Chemoradiotherapy for Stage III-IV Head and Neck Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase I Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SCCC-02308, SCCC-02308, NCT00896350
21.	Dose-escalation Study of Oral CX-4945 Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C4-08-001, NCT00891280
22.	Sirolimus and Cetuximab in Advanced Malignancies Phase: Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2009-0226, NCT00940381
23.	MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer Phase: Phase I Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000654169, UPCC-808258, 808258, NCT00984074
24.	Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: M06-10083, NCT01017185
25.	First in Man Study of SAR566658 Administered Every 3 Weeks in Patients With DS6-positive and Refractory Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TED10499, U1111-1116-4129, 2011-003891-35, NCT01156870